Phoenix Molecular Designs

OverviewSuggest Edit

Phoenix Molecular Designs is a company that offers cancer therapeutics and companion diagnostics designed to treat oncology indications. The company treats an aggressive type of breast cancer, Triple-Negative Breast Cancer (TNBC), which currently has limited options.
TypePrivate
Founded2012
HQVancouver, CA
Websitephoenixmd.ca

Latest Updates

Employees (est.) (Nov 2021)15
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Phoenix Molecular Designs

Sandra E. Dunn

Sandra E. Dunn

Chief Executive Officer
Gerrit Los

Gerrit Los

Chief Scientific Officer
Michael Liggett

Michael Liggett

Chief Financial Officer
Aarthi Jayanthan

Aarthi Jayanthan

Chief Operating Officer
F. Andrew Dorr

F. Andrew Dorr

Chief Medical Officer
John Van Drie

John Van Drie

Chief Technology Officer
Show more

Phoenix Molecular Designs Office Locations

Phoenix Molecular Designs has offices in Vancouver and San Diego
Vancouver, CA (HQ)
887 Great Northern Way suite 220
Vancouver, CA
1-8755 Ash St
San Diego, CA, US
3210 Merryfield Row
Show all (3)

Phoenix Molecular Designs Financials and Metrics

Summary Metrics

Founding Date

2012

Phoenix Molecular Designs total Funding

$12 m

Phoenix Molecular Designs latest funding size

$9.3 m

Time since last funding

2 years ago

Phoenix Molecular Designs investors

Phoenix Molecular Designs's latest funding round in November 2019 was reported to be $9.3 m. In total, Phoenix Molecular Designs has raised $12 m
Show all financial metrics

Phoenix Molecular Designs Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Phoenix Molecular Designs Online and Social Media Presence

Embed Graph

Phoenix Molecular Designs News and Updates

Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board

SAN DIEGO, California and VANCOUVER, BC, March 29, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), a company on a mission to help thousands of patients and their families battling triple negative breast cancer (TNBC) by developing first-in-class RSK kinase inhibitors, today...

World-Renowned Cancer Researcher, Dr. Alan Ashworth, Joins Phoenix Molecular Designs Advisory Board

SAN DIEGO and VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their...

Phoenix Molecular Designs Announces First Patient Dosed in Phase 1b Clinical Trial of PMD-026 Taking Aim at Triple Negative Breast Cancer

SAN DIEGO and VANCOUVER, BC, Nov. 24, 2020 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced that the first patient has been dosed in their Phase 1b...

Phoenix Molecular Designs Blogs

Phoenix Molecular Designs Appoints David H. Crean, PhD, MBA and Don Rindell, MBA to its Board of Directors

OCT. 8 2021SAN DIEGO, California - VANCOUVER, British Columbia – October 7, 2021 For Immediate Release: Phoenix Molecular Designs (PhoenixMD), a clinical stage biopharmaceutical company dedicated to developing precise cancer therapeutics, today announced the appointment of David H. Crean, PhD, MBA a…

Phoenix Molecular Designs CEO and Founder, Dr. Sandra E. Dunn, Awarded a Place on the Forbes 50 over 50 Vision List for Her Life's Work in Cancer Research

Aug. 12 2021SAN DIEGO, California - VANCOUVER, British Columbia - August 12, 2020, Forbes announced today that Dr. Sandra Dunn, CEO and Founder of Phoenix Molecular Designs (PhoenixMD), has been awarded a coveted place on its inaugural 50 Over 50 Vision list. The list highlights the exceptional wome…

Phoenix Molecular Designs Appoints V.K. Gadi, M.D., Ph.D. and Naoto Tada Ueno, M.D., Ph.D., F.A.C.P. to its Advisory Board

Jul. 292021SAN DIEGO, California - VANCOUVER, British Columbia - July 29, 2021, Phoenix Molecular Designs (PhoenixMD), a clinical-stage therapeutics company dedicated to developing precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, announced the appointment of V.K. Gadi, M…

Phoenix Molecular Designs Frequently Asked Questions

  • When was Phoenix Molecular Designs founded?

    Phoenix Molecular Designs was founded in 2012.

  • Who are Phoenix Molecular Designs key executives?

    Phoenix Molecular Designs's key executives are Sandra E. Dunn, Gerrit Los and Michael Liggett.

  • How many employees does Phoenix Molecular Designs have?

    Phoenix Molecular Designs has 15 employees.

  • Who are Phoenix Molecular Designs competitors?

    Competitors of Phoenix Molecular Designs include HalioDx, Biotheranostics and Vela Diagnostics.

  • Where is Phoenix Molecular Designs headquarters?

    Phoenix Molecular Designs headquarters is located at 887 Great Northern Way suite 220, Vancouver.

  • Where are Phoenix Molecular Designs offices?

    Phoenix Molecular Designs has offices in Vancouver and San Diego.

  • How many offices does Phoenix Molecular Designs have?

    Phoenix Molecular Designs has 3 offices.